Table 1.
Baseline characteristics and risk of bias assessment of the 11 studies
| First author | Study type | N | N SMA type 1 | N SMA type 2 | N SMA type 3 | N SMA type 4 | Age, years (range) | Ambulant (%) | Scoliosis* (%) | RoB | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| De Wel 2020 | Cohort | Total | 48 | 0 | 15 | 30 | 3 | 37.1 (20–66) | 20.8 | 41.7 | Low risk |
| Treated group | 16 | 0 | 0 | 14 | 2 | 37.5 (22–66) | 43.7 | 0 | |||
| Faravelli 2019 | Case series | 12 | 0 | 0 | 12 | 0 | 28.5 (15–34.8) | 83.3 | 0 | Fair | |
| German multicenter cohorta | Cohorts | 139 | 2 | 47 | 89 | 1 | 37 (16–65) | 37 | 22 | Low risk | |
| Inan 2020 | Case series | 40 | 0 | 4 | 36 | 0 | 34.4 (19–60) | 42.5 | 15 | High risk | |
| Jochmann 2020 | Case series | 7 | 0 | 4 | 3 | 0 | 45 (20–68) | 14.2 | 42.8 | Low risk | |
| Maggi 2020 | Cohort | 116 | 0 | 13 | 103 | 0 | 34 (18–72) | 34.5 | 13.8 | Low risk | |
| Moshe-Lilie 2020 | Case series | Total | 22 | 0 | 9 | 13 | 0 | 36 (20–71) | 9 | 77 | Low risk |
| Treated group | 10 | 0 | 0 | 33 (20–48) | |||||||
| SHINE study 2020 b | Case series | 7 | 0 | 1 | 6 | 0 | 14.4 (13–16) | 71.4 | na | Fair | |
| Veerapandiyan 2020 | Case series | 12 | 1 | 4 | 7 | 0 | 22 (12–52) | 25 | 66.7 | Low risk | |
| Walter 2019 | Cohort | 19 | 0 | 0 | 19 | 0 | 34 (18–59) | 63 | 0 | Low risk | |
| Yeo 2020 | Case series | 6 | 0 | 0 | 6 | 0 | 29.9 (24.9–56.5) | 67 | 0 | Low risk | |
| Total | 428 | 3 | 97 | 324 | 4 | 12–72 | 36.4% | 24% |
N number of patients, SMA spinal muscular atrophy, na non-applicable, RoB, risk of bias
*Previous surgery for scoliosis and/or severe scoliosis
aHagenacker 2020 and Freigang 2021 reports
bMuntoni 2020 report